Recently heparin-induced thrombocytopenia type II has been diagnosed more frequently and does not exclude hemodialysis patients. Up to now, recombinant hirudin is the only available anticoagulant showing no immunologic cross reactions with heparin. However, the use of r-hirudin in hemodialysis patients with different degrees of residual renal functions is impossible using standard dosages because elimination of r-hirudin varies depending on the degree of residual renal function. Therefore the first study was carried out using consecutive r-hirudin anticoagulated hemodialyses to determine the appropriate dose of r-hirudin. Ten hemodialysis patients with creatinine clearance values ranging between 0 and 13 mL/min/1.73m 2 were anticoagulated with r-hirudin. An initial bolus of 0.1 mg/kg bwt before the first hemodialysis, resulted in an average r-hirudin blood concentration of 305 ng/mL at the end of treatment. The dose for each of the following four he-modialyses was adjusted individually to reach the minimum therapeutic r-hirudin blood concentration. At the end of these treatments the mean blood r-hirudin concentration was 422 ng/mL. The necessary mean doses ranged between 0.008 and 0.125 mg/kg bwt correlating to the creatinine clearance values of the patients. All hemodialyses of the study were effective and safe. Bleeding times determined during r-hirudin anticoagulation were significantly lower than control values measured 2 days after a heparin administration. The study proved that r-hirudin may be an efficient and safe heparin alternative as a hemodialysis anticoagulant when the individual's residual renal function is noted for dosage and dose adjustment and is controlled by drug monitoring using the ecarin clotting time.
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Recombinant hirudin (r-hirudin) a miniprotein having a molecular weight of about 7 kd, became available for clinical use in cases of heparin-induced thrombocytopenia type II (HIT II) in 1997.
Due to its different molecular structure r-hirudin does not cause immunologic cross reactions with heparins. Moreover r-hirudin offers some advantages to heparin because it acts as a direct and highly specific thrombin inhibitor without the need of cofactors like antithrombin III. Therefore first successes of the therapeutic use of r-hirudin in patients suffering from HIT II were reported (1) (2) (3) (4) (5) .
Although for several years hardly any information was published about cases of HIT II in patients undergoing regular hemodialysis therapy, recently more and more cases of HIT II have been identified in hemodialysis patients (6) (7) (8) (9) .
Due to the favorable pharmacokinetic properties of r-hirudin, like a half-time between 1 and 3 hours and missed metabolism before excretion by glomerular filtration, its use in patients with undisturbed renal function may be successful with standard doses (10) . In contrast to cases of renal impairment, the pharmacokinetic behavior of r-hirudin changes dramatically because the retention time may be prolonged considerably increasing the danger of cumulation (11) . These facts have to be considered not only in cases of acute renal dysfunction but especially in patients undergoing hemodialysis therapy with different degrees of residual renal function. Therefore, questions arise in clinical practice about the efficient and safe use of r-hirudin in regular hemodialysis therapy. The first two successive hemodialyses using r-hirudin as an anticoagulant in humans were carried out in 1989 by Thieler et al. (12) . The results were confirmed by studies of Vanholder et al. (13) and van Wyk et al. (14) who used r-hirudin only for single hemodialysis sessions.
The study presented here has included hemodialysis patients with different residual renal function showing creatinine clearance values between 0 and 13 mL/min/1.73m2.
The r-hirudin dose adjustment in five successive hemodialyses taking into consideration the residual blood concentrations of r-hirudin at the beginning of subsequent hemodialyses was investigated. The main objective of the study was to reach the minimum therapeutic r-hirudin blood concentration that allows effective hemodialyses without signs of coagulation in the extracorporeal circuit.
The Ecarin Clotting Time (ECT) was used for drug monitoring to find the minimum required blood level by means of individual dosage (15) . Results should serve as a preliminary guideline for r-hirudin dosage in hemodialysis patients with different residual renal function.
PATIENTS AND METHODS

Patients
Ten patients (aged 26-59 years, mean = 41) with end-stage renal failure on chronic hemodialysis treatment were included in the study. Inclusion criteria were out-and backflow via arteriovenous fistula and negative r-hirudin intracutaneous test. Excluded were those patients suffering from bleeding or coagulation disorders, diabetes mellitus, cancer (with positivity for HBsantigen), HIV-antigen or HCV-antibodies (with anticoagulant or nonsteroidal anti-inflammatory therapy) and pregnancy. Informed written consent was obtained as approved by the Ethics Commission of the Medical High School, Erfurt, Germany. The patients involved in the study have suffered from different renal diseases: rapid progressive glomerulonephritis (n = 2), chronic glomerulonephritis (n = 2), chronic pyelonephritis (n = 1), nephrocirrhosis of unknown origin (n = 1), nephrocirrhosis of vascular genesis (n = 3), and lupus erythematosus (n = 1). The residual diuresis amounted to 10 to 900 mL/24 hours in nine patients (creatinine clearance: 0.05-13 mL/min/1.73m2), whereas one patient was bilaterally nephrectomized.
Dialysis duration at the start of the study ranged from 8 to 82 months (mean = 36). Body surface area (BSA) ranged from 1.36 to 1.9 m2 (mean = 1.68) and dry weight from 48 to 88 kg (mean = 63). Other predialytic laboratory parameters at the start of the study amounted to 415 to 1,191 f.1mol/L serum creatinine (mean = 878), 16 .2 to 30.5 mmol/L serum urea (mean = 23.1 ), and 0.24 to 0.37 hematocrite (mean = 0.31).
Hemodialysis treatments
All patients were treated using a double-needle technique (steel-needle, outer diameter 1.5 mm) via arteriovenous-fistula (AVF) (3 patients elbow fistula, 7 patients cimino fistula). All hemodialyses of the study were performed using polysulfone low-flux dialyzers (Hemoflow F 7 in seven patients, Hemoflow F 8 in three patients, Fresenius AG, Bad Homburg, Germany) against bicarbonate dialysate (bicarbonate 33 mmol/L, glucose 10 mmol/L). The blood flow ranged from 250 to 350 mL/ min, the dialysate flow amounted to 500 mL/min. Dialysis time (8-26 hours per week, mean = 14) and dialysis frequency ( patient twice a week, 8 patients three times a week, I patient four times a week) were individual.
Study medication
For this study r-hirudin exprimed by E. coli as hirudin variant 1 with a specific activity of 13,900 ATU/mg was used. It was kindly provided by Dr. Butti, Iketon Farmaceutici Srl., Segrate, Italy.
Study design
Immediately before the first hemodialysis of the study, a r-hirudin standard bolus of 0.1 mg/kg bwt was administered to all patients via the &dquo;arterial&dquo; dialysis needle. The dose for each of the following r-hirudin anticoagulated hemodialysis was adjusted individually taking into account the current residual blood concentrations of rhirudin. They were measured immediately before starting hemodialysis treatment using ECT. The determined r-hirudin blood concentration served as a base for determining the current individual r-hirudin dose necessary to achieve the desired r-hirudin blood level at the end of hemodialysis, which also was controlled. The r-hirudin dose was adjusted so that the minimum r-hirudin blood concentration allowing an efficient hemodialysis was determined for each patient until the end of the study with attention paid to a sufficient residual dialyzer's volume (>90%) and the absence of clot formation in the bloodline systems.
For determination of the r-hirudin concentration in plasma, variables of coagulation and laboratory parameter citrated blood samples (v/v, 10:1 with 3.18% sodium citrate, Jenapharm GmbH, Jena, Germany) were withdrawn before and at the end of each hemodialysis via the dialysis needles. Platelet poor plasma was prepared by centrifuging the freshly taken blood at 2,000 g for 10 minutes and frozen at -20°C. In patients with residual renal function, urine was collected and creatinine and r-hirudin clearance values were controlled permanently during the study.
The bleeding time was measured before the first rhirudin application and during the fifth hemodialysis 2 hours after r-hirudin injection.
Blood pressure and pulse rate were determined before and after each hemodialysis. After each hemodialysis, the compression time of the puncture sites (after removing of the puncture needles from the AVF) was measured. Immediately after retransfusion the residual volume of the dialyzers was measured using compressed air to press out all of the rinse fluid. The results served as a measure for reaching the minimum effective r-hirudin blood concentration. All bloodlines were observed for clot formation.
To judge the clinical effectiveness of the r-hirudin anticoagulated hemodialyses, respective comparative values were determined during three hemodialyses under the routinely used heparin anticoagulation for each of the ten patients. Both unfractionated (bolus: 59 ± 18 IU/kg bwt followed by continuous infusion: 24 ± 6 IU/kg/h) and low-molecular weight heparin (bolus: 26 ± 4 IU/kg, infusion: 12 ± 1 IU/kg/h) were used. The applicated heparin doses were the result of exact adjustment of the optimal dose.
Determination of r-hirudin in whole blood and plasma
In whole blood, the r-hirudin content was determined using the ECT immediately after sampling. Additional measurements of the r-hirudin concentration were done in plasma using different measuring principles. (a) ECT (measurement of inhibited coagulation) (b) an ecarininduced chromogenic substrate method (measurement of inhibited amidolytic activity), and (c) a hirudin enzymelinked immunosorbent assay (ELISA) (measurement of immunologic potential).
Hirudin excretion in urine was determined using the ECT.
All clotting times were determined with a multichannel, mechanical measuring device (Cl 4, Behnk Electronic, Norderstedt, Germany). 1 . ECT. For this procedure, 0.2 mL of a blood or plasma sample were mixed with 0.08 mL Tris buffer (pH 7.5) and preincubated at 37°C for 2 minutes. Then 0.02 mL ecarin-start reagent (10 EU/mL ecarin [Pentapharm Ltd., Basel, Switzerland] dissolved in saline, 0.9% with 50 mM CaC'2) was added and the time until the beginning of coagulation was measured. Using a standard curve determined previously by addition (spiking) of different amounts of r-hirudin to the individual blood or plasma the r-hirudin content of the samples could be determined. Laboratories GmbH, Munich, Germany). The results were obtained according to the manufacturer's instructions.
Renal r-hirudin excretion
Urine was sampled in 24-hour portions throughout the study. Their r-hirudin content was measured using the ECT. To this purpose 0.01 mL of the sample were filled up with Tris to 0.08 mL, then added to 0.2 mL standard plasma, and treated in the above mentioned manner. Renal clearance of r-hirudin was determined using the following formula: Clrenhircurine x VOlurine~Cplasma x time (c = concentration; vol = volume), related to a standard body area (x1.73 BSA).
Activated partial thromboplastin time
The activated partial thromboplastin time (aPTT) was measured with a commercial kit (PTT reagent, Boehringer Mannheim GmbH, Mannheim, Germany), according to the manufacturer's instructions.
Determination of fibrinogen Measurement of the fibrinogen content of the samples was done using the Biuret method. Briefly, plasma was clotted by addition of CaCl2 and thrombin. The clot was selected, washed, and disintegrated with NaOH. Afterwards Biuret reagent was added and the absorption was measured at a wavelength of 546 nm with the UV-VIS spectrophotometer. Fibrinogen concentration was determined using a previously obtained standard curve.
Determination of further laboratory variables
Blood cell count was measured in EDTA anticoagulated blood using an automatic counter (Abbot GmbH Diagnostic, Wiesbaden, Germany). Creatinine (Jaffemethod, kinetic) and urea (urease and glutamic dehydrogenase [GLDH]) were measured in serum using a Hitachi 717 device (Boehringer Mannheim, GmbH).
Bleeding time
The bleeding time measurement was performed by making a minor, standardized incision on the patients forearm using a single-incision instrument (Surgicutt4', International Technidyne Corp., Edison, NJ, U.S.A.). During the handling a manometer cuff on the upper arm maintained a pressure of 40 mmHg. Every 30 seconds the droplets of blood were swabbed off the wound site without direct contact. Time measurement was stopped at the moment bleeding stopped.
Statistical analysis
From measured numeric parameters the range is given and the mean ± SD is calculated. The tests for significant differences were performed using the Mann-Whitney U test. Statistical significance was accepted for p < .05. In case of usefulness, values were correlated by single linear regression analysis.
RESULTS
R-hirudin blood concentration and adapted individual r-hirudin dosage
The initial hemodialysis treatments of the study were performed with a standard r-hirudin dose of 0.1 mg/kg bwt for all patients, which resulted in an average rhirudin blood concentration of 305 ng/mL ( Table 1 ). The residual r-hirudin blood concentrations determined immediately before the following hemodialyses served as the starting point for individual dosage modifications to reach the lowest efficient blood level. They varied between 0 and 370 ng/mL. At the end of all of these hemodialyses with individual doses, the mean r-hirudin blood concentration was 422 ng/mL ± 73 ng/mL. In contrast to the relatively small variations in the reached concentrations, the required doses varied in range from 0.008 to 0.125 mg/kg bwt.
Clinical efficiency of hemodialysis therapy
All r-hirudin anticoagulated hemodialyses of the study were performed effectively. Table 2 summarizes the measured parameters in comparison to the values determined during three heparin control hemodialyses. Serum creatinine and serum urea decreased during hemodialysis therapy as expected. Hematocrite and platelets increased to average 111 % and 116%, respectively. There were no significant differences to the values measured during heparin anticoagulated hemodialyses. The residual volume of the dialyzers was somewhat lower in treatments searching the minimum effective r-hirudin dose compared to those under optimal heparin dosage regime (p < .05). Only small clots without hemodynamic effects were seen more frequently at the end of the r-hirudin sessions compared to the heparin sessions.
The compression time after removing the needles from the AVF puncture sites, as well as the mean arterial blood pressure and the pulse rate, did not show any significant differences.
No adverse reactions, no thrombosis in the AVF and no bleeding event attributed to r-hirudin or heparin were seen.
R-hirudin concentration in plasma and aPTT
R-hirudin content in plasma was measured using ECT, an ecarin-induced chromogenic substrate method (ECSM), and a hirudin ELISA (Table 3) . No significant differences between the results of the three methods based on different measuring principles could be proved. The r-hirudin plasma concentrations measured at the end of the individually dosed hemodialyses II-V amounted to 673 ± 144 ng/mL (ECT), 731 ± 204 ng/mL ELISA), and 849 ± 314 ng/mL (ECSM), respectively. In contrast to the measured r-hirudin plasma concentrations, the aPTT values showed an insufficient increase between the coagulation times determined before and after hemodialyses.
R-hirudin excretion
Renal r-hirudin clearance values ranged between 0.33 and 15.15 mL/min/1.73m2, which were in close correlation to the measured creatinine clearances (Fig. 1 ).
Bleeding time
The bleeding time measured at the halftime of the fifth r-hirudin anticoagulated hemodialysis (2-5.5 minutes, mean = 3.2) was significantly shorter compared to the bleeding time before the start of the study without current anticoagulation 2 to 3 days after the last heparin application (3) (4) (5) (6) (7) (8) (9) (10) (11) .5 minutes, mean = 6.8).
Fibrinogen plasma levels
No significant differences could be found between the fibrinogen concentrations measured before the first rhirudin application and before the fifth r-hirudin anticoagulated hemodialysis therapy (4.79 ± 1.01 vs. 4.71 ±
FIG. 1. Correlation between creatinine and r-hirudin clearance
values measured in ten hemodialysis patients. 0.87 g/L). The values determined at the end of the first and the last hemodialysis of the study did not vary (6.37 ± 1.35 vs. 6.16 ± 1.31 g/L).
DISCUSSION
R-hirudin has been proven to be useful as a therapeutic agent in cases of heparin-induced thrombocytopenia (1) (2) (3) (4) (5) . Because HIT II has been diagnosed more frequently in hemodialysis patients (6, 8) , r-hirudin can also be used as an effective alternative anticoagulant for long-term applications in patients with disturbed renal function. Until now no investigations concerning the repeated use of r-hirudin and its dosage in consecutive hemodialyses were described even though this knowledge would be necessary due to the changed pharmacokinetic behavior of r-hirudin in cases of renal impairment. Renal excretion of r-hirudin is the only possibility for elimination because it is not metabolized in the organism (10, 11) . Therefore, in ten hemodialysis patients with different residual renal functions an individual dose determination for reaching minimum effective anticoagulant r-hirudin concentrations was carried out. The varying residual renal excretion was reflected in the determined creatinine and r-hirudin clearance values, which show a close linear correlation (r2 = 0.993). For adjustment of the lower margin of the therapeutic range of r-hirudin blood concentration by dose adaptation, the remaining amount of r-hirudin before each hemodialysis treatment had to be noticed. For this purpose its concentration was measured immediately before each hemodialysis to obtain a base for dosage. The measured values show the expected clear variation according to the different degrees of renal dysfunction. Therefore the adapted doses varied in the range between 0.008 and 0.125 mg/kg bwt. Looking at the measured dialyzer's residual volumes after hemodialy-ses, it becomes clear that the reached r-hirudin concentrations at the end of treatments present the lower margin of the therapeutic range for anticoagulatioin during hemodialysis therapy. Two-thirds of dialyzers had a residual volume between 90% and 100% of the maximum, the others showed results between 80% and 89%. Taking together the hemodialyses with individual-fitted dosages whose dialyzers had residual volumes >90% and did not show clot formation, the mean r-hirudin blood concentration at the end of hemodialyses amounted to 414 ng/ mL. To reach this minimum anticoagulative effective concentrations in hemodialyses, patients with a creatinine clearance <0.5 mL/min/1.73m2 required an average dose of 0.053 ± 0.015 mg/kg bwt. In the range of creatinine clearance between 0.5 and 5 mL/min/1.73m2, there is a direct correlation between r-hirudin dosage and residual renal excretion function. If this residual function is more pronounced (creatinine clearance >5 mL/min/ 1.73m2) r-hirudin doses ~0.1 mg/kg bwt had to be given.
The r-hirudin concentrations in blood and plasma measured before and at the end of each hemodialysis using the ECT in two patients with different degrees of residual renal function are shown ( Fig. 2A, B ). In the patient with a creatinine clearance of 4.5 mL/min the residual r-hirudin concentration before the following hemodialysis ranged ~ 100 ng/mL blood. Doses of about 0.1 mg/kg bwt were necessary to reach an efficient anticoagulation ( Fig. 2A ). In the other patient with the lowcreatinine clearance of 0.06 mL/min, the residual rhirudin concentrations were much higher. Only the rhirudin doses between 0.058 and 0.07 mg/kg bwt had to be given (Fig. 2B ).
The results are important because all data published so far dealt with the use of r-hirudin during a single hemodialysis (12, 13) . The first hemodialysis treatment under r-hirudin anticoagulation was done during a pharmacokinetic study in 1989 (12) after bolus application of 0.1 I mg/kg bwt, reaching a r-hirudin plasma concentration of 450 ng/mL without any problems. Vanholder et al. (13) described a dose titration of r-hirudin to the occurence of clotting. With the found effective r-hirudin dose of 0.08 mg/kg bwt, 14 patients with a creatinine clearance <7 mL/min were treated to perform a single hemodialysis. The reached r-hirudin plasma concentrations at the end of this treatment varied between 327 and 1235 ng/mL (mean = 527.7 ng/mL). Effective single hemodialysis sessions using r-hirudin as anticoagulant were published by van Wyk et al. (14) . In this investigation r-hirudin doses ~!0.15 mg/kg bwt were completely effective. The first long-term use of r-hirudin in a HIT II patient was carried out within a r-hirudin blood concentration range between about 500 and 1,000 ng/mL for more than 4 months (5) . According to the residual renal excretion function (creatinine clearance 10.3 mL/min/1.73M2) of Confirmed by this case, the present study demonstrates that r-hirudin can be used efficiently and safely as an anticoagulant during successive hemodialysis treatments. Prerequisites are the use of r-hirudin impermeable dialyzers (polysulfone low-flux, cellulose) as demonstrated in in vitro investigation and clinical applications (5, 16 ) and a drug monitoring method for exact and fast determination of the r-hirudin concentration (15) .
Therapeutic concentrations of r-hirudin during hemodialysis ranged between 400 and 1,000 ng/mL in blood and between 600 and 1500 ng/mL in plasma. Whereas the lower margin was found in this study, the upper limit where a prolongation of bleeding time occurs (3000-4000 ng/mL) is already known (17) . Controlling the rhirudin concentration in this range means that no prolongation of bleeding time will appear when patients have an efficient number of sufficient blood platelets. That is the reason why even less than the low levels of r-hirudin during the dialysis-free intervals do not cause problems. This was proved with the results of bleeding time measurement in the middle of the last r-hirudin anticoagulated hemodialysis in a state of efficient anticoagulation. The control measurement was done 2 days after a heparin anticoagulated hemodialysis without any current anticoagulation. Despite these different conditions during measurements a significant reduction of bleeding time to a physiological value of an average 3.2 minutes could be registered.
If r-hirudin use for anticoagulation during hemodialysis has to be started, for instance, in cases of HIT II or antithrombin III deficiency for the first r-hirudin anticoagulated treatment a dose of about 0.1 mg/kg bwt is sufficient independent of the renal function. The doses for the following hemodialyses have to be adapted to the residual renal function. Guiding values are about 0.07 mg/kg bwt in anuric patients and 0.1 to 0.17 mg/kg bwt in patients with pronounced residual renal excretion. In all cases the r-hirudin concentration in blood or plasma has to be controlled until the therapeutic range is reached. Afterwards r-hirudin concentration can be determined in greater intervals.
Taken together, this study proved for the first time in ten patients that r-hirudin may be an efficient and safe alternative to heparin as an anticoagulant during serial hemodialysis treatments. Reaching therapeutic r-hirudin concentrations is possible by dose adaptation considering the current creatinine clearance of the patient because it correlates well with the r-hirudin excretion. If r-hirudin impermeable hemodialyzers are used, maintenance of the therapeutic blood concentration range is easily done by concentration measurement using the ECT.
